Hormone Therapy After Borderline Ovarian Tumors

Hormone Therapy After Borderline Ovarian Tumors: A Critical Balance

When a woman undergoes surgical menopause, often in her late 30s or 40s, following removal of her ovaries due to borderline ovarian tumors (BOTs), she faces a dual challenge. She must manage an abrupt onset of severe menopausal symptoms while navigating cancer survivorship. A systematic review led by Dr. Jennifer Mejia-Gomez and a team from the University of Toronto, published in Climacteric, confronts a core dilemma: can menopause hormone therapy (MHT) safely relieve these symptoms, or does it risk tumor recurrence?

A Statistical Link Emerges for Combined Hormone Therapy

The research team analyzed 11 studies to investigate MHT’s relationship with BOTs. Their findings reveal a complex and inconsistent picture. Six of the included studies reported a statistically significant link between MHT use and increased odds of developing a BOT, while five did not. This inconsistency across studies signals low certainty in the evidence.

When the researchers separated MHT by type, a more distinct pattern emerged. Combined estrogen-progestin therapy showed a stronger, more consistent positive association, with an odds ratio of 1.426. This means that, based on this pooled data, women using combined MHT had 42.6% higher odds of having a BOT compared to non-users. In contrast, estrogen-only therapy showed no statistically significant association. This distinction is important for clinical discussions, as the biological effects of adding a progestin may differ.

The review’s authors, including Dr. Walter Wolfman of Mount Sinai Hospital, explicitly caution that this observed statistical association does not prove causation. The overall quality of evidence is graded as “very low,” meaning any conclusions drawn from it are highly uncertain and require careful interpretation.

A Stark Data Gap for Survivors Seeking Symptom Relief

Perhaps the most critical finding for patients and clinicians is the near-total absence of safety data for MHT use after a BOT diagnosis and surgery. The surgical removal of ovaries triggers immediate and often severe surgical menopause, raising risks like intense vasomotor symptoms, vaginal atrophy, rapid bone loss, and long-term cardiovascular harm. While MHT is the most effective treatment for these consequences, its use in this population is clouded by fear.

“Postsurgical safety data are limited,” the authors write. Astonishingly, not a single study in their review addressed the question of BOT recurrence in relation to MHT use. Only one observational study evaluated survival, finding no adverse association, but this single data point is insufficient for reassurance. This gap leaves physicians and patients in a difficult position, forced to make decisions without clear evidence on whether MHT might stimulate residual borderline cells.

Navigating Care Requires a Tailored, Team-Based Approach

Given the lack of definitive safety data, the review concludes that MHT decisions cannot follow a one-size-fits-all rule. Instead, they necessitate an “individualized, multidisciplinary discussion involving oncology and menopause specialists.” The goal is to balance the well-documented, significant quality-of-life benefits of MHT against its unquantified theoretical risks in this specific context.

For younger BOT survivors, the consequences of untreated surgical menopause are profound. Avoiding MHT can lead to a higher risk of osteoporosis, cardiovascular disease, cognitive decline, and a diminished quality of life. Clinicians must therefore consider non-hormonal options for symptom management as part of the conversation. For instance, cognitive behavioral therapy has proven effective for hot flushes and sleep disruption, and targeted vaginal moisturizers or lasers can address genitourinary syndrome of menopause.

If hormone therapy is considered after a thorough risk-benefit discussion, the review’s findings suggest a nuanced approach. The stronger statistical signal for combined estrogen-progestin therapy, compared to estrogen-only, might influence the choice of regimen, especially for women with a uterus who require progestin for endometrial protection.

Conclusion

The systematic review by Mejia-Gomez et al. clarifies a fraught clinical area not by providing simple answers, but by meticulously mapping the uncertainty. It confirms a statistical link between combined MHT and BOT odds but finds virtually no evidence to guide post-surgical care. For BOT survivors facing surgical menopause, treatment must be a personalized collaboration, weighing robust symptom relief against cautious, informed management of survivorship.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42258345/
https://pubmed.ncbi.nlm.nih.gov/42255316/
https://pubmed.ncbi.nlm.nih.gov/42241016/